Advertisement
Home »

Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.

Feb 19, 2024

ABOUT THE EXPERTS

  • Jun Mori

    Division of Pediatric Endocrinology and Metabolism, Children’s Medical Center, Osaka City General Hospital, Osaka, Japan.

    Yasuhisa Ohata

    Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.

    Yasuko Fujisawa

    Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

    Yukihito Sato

    Rare Disease Group, Novo Nordisk Pharma Ltd., Tokyo, Japan.

    Sebastian Röhrich

    Global Medical Affairs, Novo Nordisk Health Care AG, Zürich, Switzerland.

    Michael H Rasmussen

    Medical and Science, Rare Disease and Advanced Therapies, Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark.

    Rikke Beck Bang

    Biostatistics, Rare Disease and Advanced Therapies, Data Science, Novo Nordisk A/S, Aalborg, Denmark.

    Reiko Horikawa

    Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement